Verification evidence is still being completed.
PDF / print export
Elicera Therapeutics
Gothenburg, Sweden
- Verified lead
- Jamal El-Mosleh
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO and Co-Founder
- 2026 technical specialization
- Immuno-Oncology, CAR-T, Oncolytic Viruses, Cell Therapy, Gene Therapy, and Clinical Development
- Review cycle
- May 2026
- Full address
- World Trade Center Goteborg, Massans gata 10, floor 7, 412 51 Goteborg, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Elicera Therapeutics contact page confirming the Gothenburg address.
- Editorial note
- Elicera Therapeutics is published because official company materials confirm current leadership, Gothenburg operating address, and a real cell-and-gene-therapy platform.
Immuno-Oncology, CAR-T, Oncolytic Viruses, Cell Therapy, Gene Therapy, and Clinical Development
Official leadership disclosure, Official Gothenburg address disclosure, Clinical-stage cell and gene therapy claim
Elicera Therapeutics is published because official company materials confirm current leadership, Gothenburg operating address, and a real cell-and-gene-therapy platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Gothenburg, Sweden
Elicera Therapeutics
Immuno-Oncology, CAR-T, Oncolytic Viruses, Cell Therapy, Gene Therapy, and Clinical Development · Clinical-stage cell and gene therapy platform
Elicera Therapeutics runs cell therapy development, gene therapy programs, and clinical immuno-oncology development in Gothenburg, Sweden.
- Lead
- Jamal El-Mosleh (verified ↗)
- Address
- World Trade Center Goteborg, Massans gata 10, floor 7, 412 51 Goteborg, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage cell and gene therapy platform
- Capabilities
- Cell Therapy Development · Gene Therapy Programs · Clinical Immuno-Oncology Development
- Founded
- 2018
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Jamal El-Mosleh
CEO and Co-Founder
Full addressWorld Trade Center Goteborg, Massans gata 10, floor 7, 412 51 Goteborg, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Elicera Therapeutics contact page listing the Gothenburg address.
Open sourceClinical-stage cell and gene therapy platform
Gothenburg, Sweden. Immuno-Oncology, CAR-T, Oncolytic Viruses, Cell Therapy, Gene Therapy, and Clinical Development. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Gothenburg address disclosure, Clinical-stage cell and gene therapy claim
Immuno-Oncology, CAR-T, Oncolytic Viruses, Cell Therapy, Gene Therapy, and Clinical Development
Elicera Therapeutics is published because official company materials confirm current leadership, Gothenburg operating address, and a real cell-and-gene-therapy platform.
Editorial note
Elicera Therapeutics is published because official company materials confirm current leadership, Gothenburg operating address, and a real cell-and-gene-therapy platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Cell Therapy Development
Gene Therapy Programs
Clinical Immuno-Oncology Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Cell and gene therapy workflow
Clinical program infrastructure
Immuno-oncology R&D systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Elicera Therapeutics located?
- Elicera Therapeutics operates from World Trade Center Goteborg, Massans gata 10, floor 7, 412 51 Goteborg, Sweden, Gothenburg, Sweden.
- Who runs Elicera Therapeutics?
- Elicera Therapeutics is led by Jamal El-Mosleh, CEO and Co-Founder. Verified 21 Mar 2026.
- What does Elicera Therapeutics do?
- Elicera Therapeutics runs cell therapy development, gene therapy programs, and clinical immuno-oncology development in Gothenburg, Sweden. Core capabilities: Cell Therapy Development, Gene Therapy Programs, Clinical Immuno-Oncology Development.
Editorial context
Related technical briefs
Briefs that name Gothenburg as a covered market or city.